bioAffinity Technologies (BIAF) Income from Continuing Operations (2021 - 2026)
bioAffinity Technologies has reported Income from Continuing Operations over the past 5 years, most recently at 3630610.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 36.47% to 3630610.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 15879947.0 through Mar 2026, down 63.06% year-over-year, with the annual reading at 14909754.0 for FY2025, 64.93% down from the prior year.
- Income from Continuing Operations was 3630610.0 for Q1 2026 at bioAffinity Technologies, down from 3137466.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 88052.0 in Q2 2022 and troughed at 5051084.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 2290884.0 (2023), against an average of 2568901.12.
- The largest YoY upside for Income from Continuing Operations was 53.43% in 2023 against a maximum downside of 1876.3% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 1674583.0 in 2022, then crashed by 41.72% to 2373164.0 in 2023, then fell by 25.02% to 2966897.0 in 2024, then fell by 5.75% to 3137466.0 in 2025, then decreased by 15.72% to 3630610.0 in 2026.
- Per Business Quant, the three most recent readings for BIAF's Income from Continuing Operations are 3630610.0 (Q1 2026), 3137466.0 (Q4 2025), and 5051084.0 (Q3 2025).